| Primary |
| Rheumatoid Arthritis |
68.1% |
| Product Used For Unknown Indication |
5.7% |
| Prophylaxis |
4.7% |
| Hypertension |
4.5% |
| Juvenile Arthritis |
3.4% |
| Osteoporosis |
2.2% |
| Pain |
1.9% |
| Castleman's Disease |
1.5% |
| Juvenile Idiopathic Arthritis |
1.2% |
| Diabetes Mellitus |
1.0% |
| Insomnia |
0.8% |
| Gastritis |
0.8% |
| Depression |
0.7% |
| Gastrooesophageal Reflux Disease |
0.6% |
| Still's Disease Adult Onset |
0.5% |
| Premedication |
0.5% |
| Constipation |
0.5% |
| Antibiotic Prophylaxis |
0.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.5% |
| Hyperlipidaemia |
0.4% |
|
| Death |
14.7% |
| Interstitial Lung Disease |
7.8% |
| Weight Increased |
6.6% |
| Vomiting |
6.4% |
| Myocardial Infarction |
6.0% |
| Pneumonia |
5.9% |
| Rheumatoid Arthritis |
5.3% |
| Arthralgia |
4.6% |
| Weight Decreased |
4.5% |
| Malaise |
4.2% |
| Cerebrovascular Accident |
4.1% |
| Sepsis |
4.1% |
| Pyrexia |
3.9% |
| White Blood Cell Count Decreased |
3.6% |
| Pain |
3.4% |
| Skin Ulcer |
3.2% |
| Thrombocytopenia |
3.1% |
| Pruritus |
3.0% |
| Rash |
3.0% |
| Urinary Tract Infection |
2.9% |
|
| Secondary |
| Rheumatoid Arthritis |
59.0% |
| Prophylaxis |
8.9% |
| Juvenile Arthritis |
6.6% |
| Hypertension |
4.8% |
| Product Used For Unknown Indication |
4.6% |
| Castleman's Disease |
3.0% |
| Osteoporosis |
2.5% |
| Gastritis |
1.6% |
| Pain |
1.4% |
| Diabetes Mellitus |
1.1% |
| Glaucoma |
0.9% |
| Insomnia |
0.8% |
| Antibiotic Prophylaxis |
0.8% |
| Depression |
0.7% |
| Juvenile Idiopathic Arthritis |
0.6% |
| Premedication |
0.6% |
| Constipation |
0.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.5% |
| Lung Adenocarcinoma |
0.5% |
| Still's Disease Adult Onset |
0.5% |
|
| Interstitial Lung Disease |
9.2% |
| White Blood Cell Count Decreased |
8.4% |
| Weight Increased |
6.3% |
| Cerebral Infarction |
6.3% |
| Rash |
6.1% |
| Pneumonia |
5.6% |
| Weight Decreased |
5.6% |
| Upper Respiratory Tract Inflammation |
5.4% |
| Cellulitis |
5.2% |
| Pruritus |
5.0% |
| Bronchitis |
4.9% |
| Pyrexia |
4.9% |
| Rheumatoid Arthritis |
4.1% |
| Anaemia |
3.9% |
| Death |
3.5% |
| Nasopharyngitis |
3.5% |
| Lung Neoplasm Malignant |
3.3% |
| Cerebral Haemorrhage |
3.1% |
| Subcutaneous Abscess |
3.1% |
| Hypertension |
2.9% |
|
| Concomitant |
| Rheumatoid Arthritis |
47.7% |
| Product Used For Unknown Indication |
22.3% |
| Drug Use For Unknown Indication |
4.1% |
| Juvenile Arthritis |
2.8% |
| Osteoporosis |
2.8% |
| Premedication |
2.8% |
| Prophylaxis |
2.4% |
| Gastritis Prophylaxis |
1.9% |
| Arthritis |
1.7% |
| Insomnia |
1.5% |
| Gastritis |
1.3% |
| Pain |
1.3% |
| Acute Respiratory Distress Syndrome |
1.1% |
| Nausea |
1.1% |
| Sapho Syndrome |
1.1% |
| Osteoporosis Prophylaxis |
0.9% |
| Thyroid Hormone Replacement Therapy |
0.9% |
| Antiviral Prophylaxis |
0.7% |
| Cardiovascular Disorder |
0.7% |
| Depression |
0.7% |
|
| Interstitial Lung Disease |
8.8% |
| Rheumatoid Arthritis |
8.8% |
| Sapho Syndrome |
8.8% |
| Anaemia |
5.9% |
| Drug Ineffective |
5.9% |
| Overdose |
5.9% |
| Thrombocytopenia |
5.9% |
| Hypoaesthesia |
4.4% |
| Injection Site Pain |
4.4% |
| Shock |
4.4% |
| Therapeutic Response Decreased |
4.4% |
| Urticaria |
4.4% |
| Vitamin D Decreased |
4.4% |
| Vomiting |
4.4% |
| Wound |
4.4% |
| Abdominal Discomfort |
2.9% |
| Autoimmune Disorder |
2.9% |
| Breast Cancer Stage Ii |
2.9% |
| Dizziness |
2.9% |
| Hypersensitivity |
2.9% |
|
| Interacting |
| Prophylaxis |
30.2% |
| Rheumatoid Arthritis |
22.4% |
| Castleman's Disease |
12.9% |
| Hypothyroidism |
12.9% |
| General Anaesthesia |
6.9% |
| Product Used For Unknown Indication |
6.0% |
| Hypertension |
3.4% |
| Juvenile Arthritis |
3.4% |
| Diabetes Mellitus |
1.7% |
|
| Thrombosis |
31.3% |
| Pain |
25.0% |
| Paraesthesia |
25.0% |
| Alanine Aminotransferase Increased |
12.5% |
| Transaminases Increased |
6.3% |
|
